89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases... Show more
On August 14, 2025, the Stochastic Oscillator for ETNB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ETNB advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
ETNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ETNB as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ETNB turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ETNB entered a downward trend on August 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.521) is normal, around the industry mean (20.126). P/E Ratio (0.000) is within average values for comparable stocks, (52.590). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.088). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (327.236).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ETNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ETNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FRMPX | 29.32 | 0.04 | +0.14% |
Nuveen Small Cap Growth Opp A | |||
HWAIX | 42.24 | 0.01 | +0.02% |
Hotchkis & Wiley Value Opps Instl | |||
UBVSX | 87.44 | N/A | N/A |
Undiscovered Managers Behavioral Val I | |||
HDCEX | 10.02 | N/A | N/A |
Rational Equity Armor Fund C | |||
DFUEX | 31.82 | -0.09 | -0.28% |
DFA US Social Core Equity 2 Portfolio |
A.I.dvisor indicates that over the last year, ETNB has been loosely correlated with AKRO. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ETNB jumps, then AKRO could also see price increases.
Ticker / NAME | Correlation To ETNB | 1D Price Change % | ||
---|---|---|---|---|
ETNB | 100% | +3.02% | ||
AKRO - ETNB | 60% Loosely correlated | +1.57% | ||
IDYA - ETNB | 54% Loosely correlated | +5.15% | ||
IRON - ETNB | 50% Loosely correlated | +0.95% | ||
BEAM - ETNB | 49% Loosely correlated | +12.62% | ||
CRNX - ETNB | 49% Loosely correlated | +3.97% | ||
More |